



**Natco Pharma Limited**  
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

**Ref:PR/22/2015**

**Press Release**

**SUPREME COURT AGREES WITH NATCO AND DENIES PETITION FOR CERTIORARI  
ON GENERIC TAMIFLU PATENT**

***Hyderabad, India, March 10<sup>th</sup>, 2015***

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announced today that it is pleased with the U.S. Supreme Court's decision to deny certiorari for the generic version of Tamiflu® oral capsules (oseltamivir phosphate). Natco is partnered with Alvogen in the USA for marketing of this product. The denial was issued on March 9, 2015, in the case of Gilead Sciences, Inc. et al. v. Natco Pharma Limited et al, No. 14-647.

Natco has already received a tentative approval on March 14, 2014, for Oseltamivir Phosphate Capsules USP, 30 mg (base), 45 mg (base) and 75 mg (base) on the Abbreviated New Drug Application (ANDA) containing a paragraph IV certification filed with the United States Food & Drug Administration (USFDA).

In the April 22, 2014 Federal Circuit decision, Circuit Judges Chen and Prost agreed with Natco and Alvogen's position that an earlier filed and earlier expiring patent qualifies as an obviousness-type double patenting reference for a later filed, and later expiring patent. The Supreme Court today declined to review the Federal Circuit's decision. The case remains pending in the District of New Jersey where the validity of U.S. Patent No. 5,763,483 continues to be challenged.

---

Forwarded for favor of publication

**For NATCO Pharma Limited**

A handwritten signature in black ink, appearing to read "M Adinarayana".

M Adinarayana  
Company Secretary &  
Vice President (Legal & Corp Affairs)